BioSpace News Archive

invIOs GmbH, a privately held biotechnology company developing novel therapies for cancer, is pleased to announce it will commence operations on 1 January 2022.

Biophytis SA announces to enter into first regulatory activities to advance Sarconeos development in sarcopenia from Phase 2 to Phase 3 development, with a Type B/End-of-Phase 2 meeting withFDA, USA, on January 24th, 2022, to discuss SARA-INT results and the Phase 3 protocol design.

AlloVir announced that Augustin Melian, MD, Chief Medical Officer, has decided to leave the company at the end of this year.

DENTSPLY SIRONA Inc., announced that its Board of Directors declared a quarterly cash dividend of $0.11 per share of common stock, an indicated annual rate of $0.44 per share.

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), today announced the launch of the NAV3-33 Phase 3 clinical trial titled “Evaluation of Tc99m Tilmanocept Imaging for the Early Prediction of Anti-TNFα Therapy Response in Patients with Moderate to Severe Active Rheumatoid Arthritis (RA).”

Taysha Gene Therapies, Inc. (Nasdaq: TSHA),, today announced the initiation of clinical development of TSHA-118 for the treatment of CLN1 disease under a recently approved Clinical Trial Application (CTA).

BIOASIS TECHNOLOGIES INC. is pleased to announce that all resolutions were passed by requisite majority at its annual general meeting held earlier in New Haven, Conn., United States.

Geron Corporation reported that it has granted a non-statutory stock option to purchase an aggregate of 50,000 shares of Geron common stock as an inducement to a newly hired employee in connection with commencement of employment with the Company.

Scitara Corporation, an innovator in laboratory digital transformation, has launched a ground-breaking advanced integration platform that creates a new industry category for the laboratory and scientific communities.

Coherus BioSciences, Inc., announced that effective Dec. 13, 2021, the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 367,000 shares of the common stock of the Company to newly hired employees with a per share exercise price of $17.06, the closing trading price on the grant date.